At a glance
ClinicalIndex Comparison RecordN/ACompleted· 101 enrolled
Drug / intervention
ReFacto AF (Moroctocog alfa)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pharmacovigilance Evaluation Of Refacto Af (Registered) In Germany And Austria
In Brief
An observational study evaluating ReFacto AF (Moroctocog alfa) for Hemophilia A. Completed, enrolled 101 participants across 24 sites in 2 countries.
Detailed Summary
The purpose of this observational study is to describe the incidence of adverse events among patients treated with Refacto AF in usual health care settings in Germany and Austria.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHemophilia A
CountriesAustria, Germany
Collaborators--
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2009
Enrollment StartJul 2009
Primary CompletionOct 2016
TodayJul 2026
First PostedMay 7, 2009
Enrollment StartJul 17, 2009
Primary CompletionOct 19, 2016
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 17.2 years ago
Interventions
ReFacto AF (Moroctocog alfa)drug
Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively